Scopio Labs, a Tel Aviv, Israel-based developer of full-field digital cell morphology imaging and analysis platforms, raised $42M in funding.
The round, which brought the total amount to $130M, was led by Fortissimo Capital, with participation from existing investors.
The company intends to use the funds to accelerate its market penetration and expand its global footprint. This includes scaling sales and marketing efforts and strengthening customer support. The funding will support the continued development of Scopio Labs’ digital morphology platform and the creation of products to meet the evolving needs of hematology laboratories and hospitals.
Led by CEO Itai Hayut, Scopio Labs is a provider of full-field imaging accelerating the digital transformation of hematology laboratories worldwide. By supporting laboratory scientists and clinicians with scale and depth in digital cell morphology, its platforms enable timely detection of blood-related medical conditions, expediting patients’ access to life-saving treatments.
Scopio’s platform uses computational photography to provide unprecedented digital imaging of thousands of cells. Lab practitioners, therefore, have a full-field view of all regions of clinical interest on the sample at the highest resolution, supplanting the need for manual microscopy. Scopio delivers workflow efficiency in blood cell analysis designed to enhance remote consultation and collaboration, expedite decision-making, and bolster patient care. This platform not only amplifies diagnostic capabilities but also significantly curtails the time and expenses traditionally associated with manual methods.
FinSMEs
25/07/2024